List of Excipients in Branded Drug NISOLDIPINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
United Research Laboratories Inc	NISOLDIPINE	nisoldipine	0677-1978	CARNAUBA WAX
United Research Laboratories Inc	NISOLDIPINE	nisoldipine	0677-1978	FERRIC OXIDE YELLOW
United Research Laboratories Inc	NISOLDIPINE	nisoldipine	0677-1978	GLYCERYL BEHENATE
United Research Laboratories Inc	NISOLDIPINE	nisoldipine	0677-1978	HYPROMELLOSE
United Research Laboratories Inc	NISOLDIPINE	nisoldipine	0677-1978	LACTOSE

Generic Drugs Containing NISOLDIPINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	nisoldipine	0378-2096	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	nisoldipine	0378-2096	FD&C YELLOW NO. 6
Mylan Pharmaceuticals Inc	nisoldipine	0378-2096	HYDROXYPROPYL CELLULOSE
Mylan Pharmaceuticals Inc	nisoldipine	0378-2096	HYPROMELLOSE 2208
Mylan Pharmaceuticals Inc	nisoldipine	0378-2096	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in NISOLDIPINE?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
3	FD&C BLUE NO. 2
2	FD&C BLUE NO. 2--ALUMINUM LAKE
3	FD&C YELLOW NO. 6
2	FERRIC OXIDE YELLOW

Excipient Strategy and Commercial Opportunities for NISOLDIPINE

Last updated: March 1, 2026

What are the key excipient considerations for Nisoldipine formulations?

Nisoldipine, a dihydropyridine calcium channel blocker, is formulated primarily for oral administration in sustained and immediate-release forms. Excipient selection is critical for stability, bioavailability, and patient tolerability.

Key excipients include:

• Lactose: Used as a filler in tablet formulations. Its solubility supports rapid dissolution but can cause issues in lactose-intolerant populations.
• Microcrystalline cellulose (MCC): Also a filler and binder, MCC provides compressibility and flow properties.
• Croscarmellose sodium: Employed as a disintegrant to facilitate tablet breakup in GI fluid.
• Magnesium stearate: Serves as a lubricant to prevent sticking during manufacturing.
• Polyvinylpyrrolidone (PVP): Used in tablet films or coating for improved integrity.

Formulation challenges involve moisture sensitivity, stability of the active drug, and ensuring sustained-release profiles where applicable.

How do excipient choices influence formulation development?

Excipient profiles affect:

• Stability: Lactose can undergo Maillard reactions with amino groups in drug substances, potentially reducing drug stability.
• Bioavailability: Disintegration time, modulated by disintegrants like croscarmellose sodium, impacts plasma concentration profiles.
• Manufacturability: Excipient properties like flowability and compressibility influence process efficiency and batch consistency.

Selection hinges on balancing pharmacokinetics, patient compliance, and manufacturing robustness.

Are there ongoing innovations or alternative excipient strategies?

Emerging strategies include:

• Use of complex co-processed excipients: Combining disintegrants, binders, and lubricants to streamline formulation and improve performance.
• Lipid-based excipients: To develop lipid formulations that may enhance bioavailability, especially in poorly soluble derivatives.
• Polymer-based matrices: For controlled-release formulations via hydrophilic or hydrophobic polymer systems.

This approach aims to optimize release kinetics and enhance bioavailability for different patient populations.

What commercial opportunities do excipient strategies unlock for Nisoldipine?

Key opportunities:

• Improved formulations: Developing more stable, bioavailable, and patient-friendly dosage forms can open new market segments.
• Different release profiles: Extended-release (ER) or controlled-release (CR) formulations match chronic hypertension management needs, offering patent extensions and premium pricing.
• Market differentiation: Innovations in excipient use can lead to formulations with lower excipient-related side effects or allergenic potential, expanding target demographics.
• Regulatory advantages: Demonstrating excipient compatibility and stability can streamline approval, especially for generic formulations seeking bioequivalence.

The strategic focus should align formulation advancements with clinical needs and patent protections to maximize market penetration.

How do regulatory considerations influence excipient choices?

Regulatory agencies such as the FDA and EMA prioritize:

• GRAS status (Generally Recognized As Safe) for excipients.
• Limitations on certain excipients (e.g., lactose for lactose-intolerant patients).
• Comprehensive stability and compatibility data to support the safety and efficacy of formulations.
• Documentation of excipient source and manufacturing process for consistency and traceability.

Compliance ensures market access and minimizes legal risks associated with excipient-related adverse events or stability failures.

Summary of key points

Aspect	Details
Main excipients	Lactose, MCC, croscarmellose sodium, magnesium stearate, PVP
Formulation challenges	Moisture sensitivity, drug stability, controlled-release development
Innovation pathways	Co-processed excipients, lipid-based carriers, polymer matrices
Market opportunities	Enhanced bioavailability, patient compliance, extended-release formats
Regulatory factors	GRAS compliance, stability data, source traceability

Key Takeaways

• Excipient selection directly impacts Nisoldipine formulation stability, bioavailability, and patient acceptance.
• Innovation in excipient technology offers potential to develop differentiated products, especially sustained or controlled-release forms.
• Regulatory compliance influences excipient choice; understanding agency guidelines is essential.
• Advancements in formulation can enable access to new markets and extend product lifecycle.
• Strategic formulation development aligns with clinical needs, market demands, and regulatory pathways.

FAQs

Q1: What are the primary excipients used in Nisoldipine tablets?
Lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and PVP are standard excipients.

Q2: How can excipient choices improve drug stability?
Selecting excipients compatible with Nisoldipine and resistant to interactions reduces degradation pathways, enhancing shelf life.

Q3: What innovation opportunities exist in Nisoldipine formulations?
Lipid-based delivery, co-processed excipients, and polymer-controlled release matrices can improve formulations.

Q4: How do excipients influence regulatory approval?
Regulatory agencies require excipients to meet safety standards (GRAS), with thorough documentation of sources and stability data.

Q5: What are the commercial benefits of developing sustained-release Nisoldipine formulations?
They can increase patient compliance, provide extended market exclusivity, and create premium product offerings.

References

[1] Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients.
[2] European Medicines Agency. (2021). Excipients in the dossier for marketing authorization.
[3] Kuang, R., Sobczak, H., & Wu, W. (2020). Excipient compatibility and stability considerations for controlled-release formulations. Journal of Pharmaceutical Sciences, 109(4), 1324–1332.